FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Williams Eugene
2. Date of Event Requiring Statement (Month/Day/Year)
07/07/2022
3. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [PMN]
(Last)
(First)
(Middle)
C/O PROMIS NEUROSCIENCES INC.,, 1920 YONGE STREET, SUITE 200
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chairman and CEO
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

TORONTO, A6 M4S 3E2
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Shares 153,930
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy)   (2) 07/06/2025 Common Shares 78,822 $ 2.43 (1) D  
Option (right to buy)   (3) 07/31/2025 Common Shares 36,988 $ 3.9 (1) D  
Option (right to buy)   (4) 03/29/2028 Common Shares 16,667 $ 28.2 (1) D  
Option (right to buy)   (5) 02/10/2032 Common Shares 50,000 $ 8.4 (1) D  
Warrants (right to buy) 08/09/2017 08/09/2022 Common Shares 833 $ 18 (1) D  
Warrants (right to buy) 04/30/2018 04/30/2023 Common Shares 556 $ 28.8 (1) D  
Warrants (right to buy) 01/22/2019 01/22/2024 Common Shares 1,927 $ 28.8 (1) D  
Warrants (right to buy) 05/31/2019 12/31/2024 Common Shares 1,111 $ 21 (1) D  
Warrants (right to buy) 03/05/2021 11/05/2026 Common Shares 3,472 $ 12 (1) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Williams Eugene
C/O PROMIS NEUROSCIENCES INC.,
1920 YONGE STREET, SUITE 200
TORONTO, A6 M4S 3E2
  X     Chairman and CEO  

Signatures

/s/ Jason L. Langford, Attorney-in-Fact for Eugene Williams 07/07/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Conversion or exercise price is in Canadian dollars.
(2) The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 6, 2015.
(3) The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 31, 2015.
(4) The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on March 29, 2018.
(5) The option agreement provides that the options become exercisable in 48 equal monthly installments beginning one month after the grant. The option was granted on February 10, 2022.
 
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.